Rheumatoid Arthritis Dose Ranging Study (0663-086)(COMPLE... | NCT00264147 | Trialant
NCT00264147
Sponsor
Organon and Co
Status
Completed
Last Update Posted
Feb 9, 2022Actual
Enrollment
761Actual
Phase
Phase 2
Conditions
Rheumatoid Arthritis
Interventions
etoricoxib
etoricoxib
etoricoxib
etoricoxib
Comparator: placebo
etoricoxib
Comparator: diclofenac
Countries
Not provided
Protocol Section
Identification Module
NCT ID
Results Section
Participant Flow Module
Pre-assignment Details
Annotation Section
No data available
No data is available for this block.
Document Section
No data available
No data is available for this block.
Derived Section
Miscellaneous Info Module
Version Holder
NCT00264147
Obsolete or Duplicate NCT IDs
Not provided
Organization Study
0663-086
Secondary IDs
ID
Type
Description
Link
2005_077
Brief Title
Rheumatoid Arthritis Dose Ranging Study (0663-086)(COMPLETED)
Official Title
A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Parallel-Group, 12-Week Study to Assess the Clinically Effective Dose Range of Etoricoxib and to Assess Its Safety and Tolerability in Patients With Rheumatoid Arthritis
Acronym
Not provided
Organization
Organon and CoINDUSTRY
Status Module
Record Verification Date
Feb 2022
Overall Recruitment Status or Expanded Access Status
Completed
Last Known Status
Not provided
Delayed Posting
Not provided
Why Stopped
Not provided
Expanded Access Info
No
Start Date
Jan 2006
Primary Completion Date
Mar 2008Actual
Completion Date
Mar 2008Actual
First Submitted Date
Dec 9, 2005
First Submission Date that Met QC Criteria
Dec 9, 2005
First Posted Date
Dec 12, 2005Estimated
Results Waived
Not provided
Results First Submitted Date
Mar 19, 2009
Results First Submitted that Met QC Criteria
May 22, 2009
Results First Posted Date
Jul 7, 2009Estimated
Certification/Extension (aka Delayed Results) First Submitted Date
Not provided
Certification/Extension First Submitted that Passed QC Review
Not provided
Certification/Extension First Posted Date
Not provided
Last Update Submitted Date
Feb 7, 2022
Last Update Posted Date
Feb 9, 2022Actual
Sponsor/Collaborators Module
Responsible Party, by Official Title
Sponsor
Lead Sponsor
Organon and CoINDUSTRY
Collaborators
Not provided
Oversight Module
No data available
No data is available for this block.
Description Module
Brief Summary
To assess the clinically active dose range of study medication in the treatment of patients with rheumatoid arthritis.
Detailed Description
Not provided
Conditions Module
Conditions
Rheumatoid Arthritis
Keywords
Arcoxia
Design Module
Study Type
Interventional
Number of References to an Expanded Access Study
Not provided
Expanded Access Types
Not provided
Patient Registry
Not provided
Target Follow-Up Duration
Not provided
Phases
Phase 2
Interventional Study Design
Allocation
Biospecimen
No data available
No data is available for this block.
Enrollment
761Actual
Arms/Interventions Module
Arm Groups
Label
Type
Description
Intervention Names
Period I: 1
Experimental
etoricoxib
Drug: etoricoxib
Period I: 2
Experimental
etoricoxib
Drug: etoricoxib
Period I: 3
Experimental
etoricoxib
Drug: etoricoxib
Period I: 4
Experimental
etoricoxib
Drug: etoricoxib
Period I: 5
Placebo Comparator
Placebo
Drug: Comparator: placebo
Period II: 1
Experimental
etoricoxib
Drug: etoricoxib
Period II: 2
Active Comparator
Interventions
Name
Type
Description
Arm Group Labels
Other Names
etoricoxib
Drug
Period I: Arm 1: etoricoxib 10 mg tablet once daily. 12 weeks of treatment.
Period I: 1
Outcomes Module
Primary Outcomes
Measure
Description
Time Frame
Proportion of Patients Who Met the ACR20 Responder Index Criteria
Proportion of Patients Who Met the American College of Rheumatology Response Index (20%) Criteria (ACR20) (Based on the Time-Weighted Average Responses of the 12-Week Treatment I Period and Completed the Treatment I Period) (All Patients-Treated Population)
12 weeks
Secondary Outcomes
Measure
Description
Time Frame
Tender Joint Count (Out of 68 Joints) Time-Weighted Average Change From Baseline (Flare/Randomization Visit) in the 12-Week Treatment Period (All Patients-Treated Population)
Time-weighted average change from baseline across Weeks 2, 7, and 12
Swollen Joint Count (Out of 66 Joints) Time-Weighted Average Change From Baseline (Flare/Randomization Visit) in the 12-Week Treatment Period (All Patients-Treated Population)
Other Outcomes
Not provided
Eligibility Module
Eligibility Criteria
Inclusion Criteria:
Patient with diagnosed rheumatoid arthritis (RA) for at least 6 months prior who is otherwise judged to be in general good health and who is currently taking nonsteroidal anti-inflammatory drugs (NSAIDS) to treat his/her RA symptoms
Patient will need to stop taking these medications in order to participate, but can continue taking his/her other anti-rheumatic medications as long as they have been stable for certain periods of time
Exclusion Criteria:
Patients with a disease or medical condition(s) that could worsen or interfere with the evaluation of the effectiveness of study medication are not allowed to participate
Greenwald M, Peloso PM, Mandel D, Soto O, Mehta A, Frontera N, Boice JA, Zhan XJ, Curtis SP. Further assessment of the clinically effective dose range of etoricoxib: a randomized, double-blinded, placebo-controlled trial in rheumatoid arthritis. Curr Med Res Opin. 2011 Oct;27(10):2033-42. doi: 10.1185/03007995.2011.614935. Epub 2011 Sep 12.
Patients must have taken Non Steroidal Anti-inflammatory Drugs (NSAIDs) at a therapeutic labeled dose on a regular basis and demonstrated a clinical response in the past and at screening. Following a protocol-specified "washout," patients must have demonstrated disease activity and worsening in symptoms of Rheumatoid Arthritis from the screening.
Recruitment Details
90 multicenter rheumatologists: US (71), Canada (14), Colombia (3), Switzerland (2), recruited 761 study patients from their patient pool and through advertising. First Patient In 04-Jan-2006, Last Patient Last Visit 26-Mar-2008.
Type of Units Analyzed
Not provided
Arm/Group Information
ID
Title
Description
FG000
Placebo
Treatment I: Placebo orally once daily
FG001
Etoricoxib 10 mg
Treatment I: Etoricoxib 10 mg orally once daily
FG002
Etoricoxib 30 mg
Treatment I: Etoricoxib 30 mg orally once daily
FG003
Etoricoxib 60 mg
Treatment I: Etoricoxib 60 mg orally once daily
FG004
Etoricoxib 90 mg
Treatment I and II: Etoricoxib 90 mg orally once daily
FG005
Diclofenac 150 mg (Treatment II)
Treatment II: Diclofenac 75 mg orally twice daily
Periods
Title
Milestones
Reasons Not Completed
Treatment I Period
Type
Comment
Milestone Data
STARTED
FG000161 subjects
FG001154 subjects
FG002151 subjects
FG003140 subjects
FG004155 subjects
FG0050 subjects
COMPLETED
FG00063 subjectsRandomized to Treatment I period and remained on Treatment I period during course of study
FG00171 subjectsRandomized to Treatment I period and remained on Treatment I period during course of study
FG00274 subjectsRandomized to Treatment I period and remained on Treatment I period during course of study
FG003
NOT COMPLETED
FG00098 subjects
FG00183 subjects
FG00277 subjects
FG00372 subjects
FG004
Type
Comment
Reasons
Adverse Event
FG0003 subjects
FG0016 subjects
FG0023 subjects
FG003
Treatment II Period
Type
Comment
Milestone Data
STARTED
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG003
Baseline Characteristics Module
Baseline Analysis Population Description
Not provided
Type of Units Analyzed
Not provided
Arm/Group Information
ID
Title
Description
BG000
Placebo
Treatment I: Placebo orally once daily
BG001
Etoricoxib 10 mg
Treatment I: Etoricoxib 10 mg orally once daily
Denominators
Units
Counts
Participants
BG000
Baseline Measures
Title
Description
Population Description
Parameter Type
Dispersion Type
Unit of Measure
Calculate Percentage
Denominator Units Selected
Denominators
Classes
Age, Continuous
Mean
Outcome Measures Module
Outcome Measures
Type
Title
Description
Population Description
Reporting Status
Anticipated Posting Date
Parameter Type
Dispersion Type
Unit of Measure
Calculate Percentage
Time Frame
Units Analyzed
Denominator Units Selected
Arm/Group Information
Denominators
Classes
Analyses
Primary
Proportion of Patients Who Met the ACR20 Responder Index Criteria
Proportion of Patients Who Met the American College of Rheumatology Response Index (20%) Criteria (ACR20) (Based on the Time-Weighted Average Responses of the 12-Week Treatment I Period and Completed the Treatment I Period) (All Patients-Treated Population)
All-Patients-Treated Population
Posted
Number
Proportion of Patients
12 weeks
ID
Title
Description
OG000
Placebo
Treatment I: Placebo orally once daily
OG001
Etoricoxib 10 mg
Treatment I: Etoricoxib 10 mg orally once daily
Adverse Events Module
Frequency Threshold
2
Time Frame
Not provided
Description
Not provided
All-Cause Mortality Comment
Not provided
Arm/Groups
ID
Title
Description
Deaths (Affected)
Deaths (At Risk)
Serious Events (Affected)
Serious Events (At Risk)
Other Events (Affected)
Other Events (At Risk)
EG000
Placebo Treatment I Period
Treatment I: Placebo orally once daily
Serious Adverse Events
Term
Organ System
Source Vocabulary
Assessment Type
Notes
Statistical Information
Coronary Artery Disease
Cardiac disorders
MedDRA 10.1
Non-systematic Assessment
Other Adverse Events
Term
Organ System
Source Vocabulary
Assessment Type
Notes
Statistical Information
Abdominal Pain
Gastrointestinal disorders
MedDRA 10.1
Non-systematic Assessment
More Info Module
Limitations and Caveats
Not provided
Certain Agreements
Are all PI(s) employees of the sponsor?
No
Restriction Type
Point of Contact
Title
Organization
Phone
Extension
Email
Senior Vice President, Global Clinical Development
Merck Sharp & Dohme Corp.
1-800-672-6372
ClinicalTrialsDisclosure@merck.com
Jul 10, 2026
Removed Countries
Canada
Colombia
Puerto Rico
Switzerland
United States
Submission Tracking
No data available
No data is available for this block.
Condition Browse Module
MeSH Terms
ID
Term
D001172
Arthritis, Rheumatoid
Ancestor Terms
ID
Term
D001168
Arthritis
D007592
Joint Diseases
D009140
Musculoskeletal Diseases
D012216
Rheumatic Diseases
Browse Leaves
Not provided
Browse Branches
Not provided
Intervention Browse Module
MeSH Terms
ID
Term
D000077613
Etoricoxib
Ancestor Terms
ID
Term
D013450
Sulfones
D013457
Sulfur Compounds
D009930
Organic Chemicals
D011725
Pyridines
Browse Leaves
Not provided
Browse Branches
Not provided
Randomized
Intervention Model
Parallel Assignment
Intervention Model Description
Not provided
Primary Purpose
Treatment
Observational Model
Not provided
Time Perspective
Not provided
Masking Info
Masking
Double
Masking Description
Not provided
Who Masked
ParticipantInvestigator
diclofenac
Drug: Comparator: diclofenac
etoricoxib
Drug
Period I: Arm 2: etoricoxib 30 mg tablet once daily. 12 weeks of treatment.
Period I: 2
etoricoxib
Drug
Period I: Arm 3: etoricoxib 60 mg tablet once daily. 12 weeks of treatment.
Period I: 3
etoricoxib
Drug
Period I: Arm 4: etoricoxib 90 mg tablet once daily. 12 weeks of treatment.
Period I: 4
Comparator: placebo
Drug
Period I: Arm 5: Pbo tablet once daily. 12 weeks of treatment.
Period I: 5
etoricoxib
Drug
Period II: Arm 1: etoricoxib 90 mg tablet once daily. 12 weeks of treatment.
Period II: 1
Comparator: diclofenac
Drug
Period II: Arm 2: diclofenac 75 mg tablet twice daily. 12 weeks of treatment.
Period II: 2
Time-weighted average change from baseline across Weeks 2, 7, and 12
Patient Global Assessment of Disease Activity (0- to 100-mm Visual Analog Scale) Time Weighted Average Change From Baseline (Flare/Randomization Visit) in the 12-Week Treatment I Period (All Patients-Treated Population)
0-mm indicates very well, 100-mm indicates very poor.
Time-weighted average change from baseline across Weeks 2, 7, and 12
Investigator Global Assessment of Disease Activity (0- to 4-Likert Scale) Time Weighted Average Change From Baseline (Flare/Randomization Visit) in the 12-Week Treatment I Period (All Patients-Treated Population)
0 indicates very well, 4 indicates very poor.
Time-weighted average change from baseline across Weeks 2, 7, and 12
Patient Global Assessment of Pain (0- to 100-mm Visual Analog Scale) Time Weighted Average Change From Baseline (Flare/Randomization Visit) in the 12-Week Treatment I Period (All Patients-Treated Population)
0-mm indicates very well, 100-mm indicates very poor.
Time-weighted average change from baseline across Weeks 2, 7, and 12
Derived
Kvien TK, Greenwald M, Peloso PM, Wang H, Mehta A, Gammaitoni A. Do COX-2 inhibitors provide additional pain relief and anti-inflammatory effects in patients with rheumatoid arthritis who are on biological disease-modifying anti-rheumatic drugs and/or corticosteroids? Post-hoc analyses from a randomized clinical trial with etoricoxib. BMC Musculoskelet Disord. 2015 Feb 13;16:26. doi: 10.1186/s12891-015-0468-7.
68 subjects
Randomized to Treatment I period and remained on Treatment I period during course of study
FG00499 subjectsRandomized to Treatment I period and remained on Treatment I period during course of study
FG005149 subjectsEtoricoxib 10 mg (34), 30 mg (37), 60 mg (29), and placebo (49) reassigned to diclofenac (149)
COMPLETED
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG004147 subjects
FG005116 subjects
NOT COMPLETED
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG00433 subjects
FG00533 subjects
Type
Comment
Reasons
Adverse Event
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG0049 subjects
FG0059 subjects
Laboratory Adverse Event
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG004
Lack of Efficacy
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG004
Lost to Follow-up
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG004
Withdrawal by Subject
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG004
Pre-scheduled total hip replacement
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG004
BG002
Etoricoxib 30 mg
Treatment I: Etoricoxib 30 mg orally once daily
BG003
Etoricoxib 60 mg
Treatment I: Etoricoxib 60 mg orally once daily
BG004
Etoricoxib 90 mg
Treatment I: Etoricoxib 90 mg orally once daily
BG005
Total
Total of all reporting groups
161
BG001154
BG002151
BG003140
BG004155
BG005761
Standard Deviation
years
Title
Denominators
Categories
Title
Measurements
BG00057.4± 11.80
BG00158.7± 11.92
BG00256.2± 11.17
BG00357.7± 10.96
BG00454.9± 12.54
BG00557.0± 11.75
Sex: Female, Male
Count of Participants
Participants
Title
Denominators
Categories
Title
Measurements
Female
BG000136
BG001117
BG002126
BG003112
BG004122
BG005613
Male
BG00025
BG00137
BG00225
BG00328
BG004
American Rheumatism Association Functional Class
Class I: Completely able to perform usual activities of daily living (self care, vocational, and avocational), Class II: Able to perform usual self-care and vocational activities, but limited in avocational activities, Class III: Able to perform usual self-care activities, but limited in vocational and avocational activities
Number
Participants
Title
Denominators
Categories
Class I
Title
Measurements
BG00044
BG00149
BG00249
BG00341
BG00438
BG005221
Class II
Title
Measurements
BG000102
BG00183
BG00283
BG003
Class III
Title
Measurements
BG00015
BG00122
BG00219
BG003
Corticosteroid User
Number
Participants
Title
Denominators
Categories
Yes
Title
Measurements
BG00050
BG00150
BG00242
BG00341
BG00449
BG005232
No
Title
Measurements
BG000111
BG001104
BG002109
BG003
Disease Modifying Antirheumatic Drug User
Number
Participants
Title
Denominators
Categories
Yes
Title
Measurements
BG000133
BG001129
BG002122
BG003114
BG004131
BG005629
No
Title
Measurements
BG00028
BG00125
BG00229
BG003
Disease Modifying Antirheumatic Drug or Corticosteroid User
Number
Participants
Title
Denominators
Categories
Yes
Title
Measurements
BG000139
BG001134
BG002126
BG003119
BG004136
BG005654
No
Title
Measurements
BG00022
BG00120
BG00225
BG003
Methotrexate User
Number
Participants
Title
Denominators
Categories
Yes
Title
Measurements
BG00099
BG00191
BG00296
BG00393
BG00493
BG005472
No
Title
Measurements
BG00062
BG00163
BG00255
BG003
Race/Ethnicity
Number
participants
Title
Denominators
Categories
Asian
Title
Measurements
BG0001
BG0010
BG0021
BG0031
BG0041
BG0054
Black
Title
Measurements
BG0005
BG0018
BG0023
BG003
White
Title
Measurements
BG000114
BG001106
BG002121
BG003
Hispanic
Title
Measurements
BG00041
BG00139
BG00225
BG003
Native American
Title
Measurements
BG0000
BG0010
BG0021
BG003
Indian
Title
Measurements
BG0000
BG0011
BG0020
BG003
Rheumatoid Factor
Number
Participants
Title
Denominators
Categories
Positive
Title
Measurements
BG000120
BG001117
BG002121
BG003120
BG004121
BG005599
Negative
Title
Measurements
BG00040
BG00137
BG00230
BG003
Not Reported
Title
Measurements
BG0001
BG0010
BG0020
BG003
Smoking Status
Number
Participants
Title
Denominators
Categories
Current
Title
Measurements
BG00027
BG00128
BG00229
BG00323
BG00422
BG005129
Ex-User
Title
Measurements
BG00053
BG00146
BG00242
BG003
Non-User
Title
Measurements
BG00081
BG00180
BG00280
BG003
Body Weight
Mean
Standard Deviation
Kilograms
Title
Denominators
Categories
Title
Measurements
BG00076.42± 16.54
BG00176.12± 18.48
BG00277.36± 20.00
BG00375.72± 19.54
BG00477.97± 18.61
BG00576.73± 18.58
Duration of Rheumatoid Arthritis (Years)
Mean
Standard Deviation
Years
Title
Denominators
Categories
Title
Measurements
BG00010.0± 9.78
BG00110.1± 9.76
BG00211.2± 8.40
BG00310.3± 10.18
BG0049.9± 9.98
BG00510.3± 9.62
Height
Mean
Standard Deviation
Centimeters
Title
Denominators
Categories
Title
Measurements
BG000161.93± 9.71
BG001163.63± 8.55
BG002164.57± 9.13
BG003162.96± 9.22
BG004163.49± 10.04
BG005163.30± 9.37
Investigator Global Assessment of Disease Activity (0 to 4 - Likert Scale)
Patient Global Assessment of Disease Activity (0-To- 100 Millimeter Visual Analog Scale)
(0- to 100-mm Visual Analog Scale) 0 mm= No pain, 100 mm= Extreme pain
Mean
Standard Deviation
units on a scale
Title
Denominators
Categories
Title
Measurements
BG00066.08± 18.67
BG00169.28± 19.37
BG00266.56± 20.47
BG00366.60± 19.58
BG00465.42± 18.45
BG00566.79± 19.30
Patient Global Assessment of Pain (0- To- 100-mm Visual Analog Scale)
(0- to 100-mm Visual Analog Scale) 0 mm= No pain, 100 mm= Extreme pain
Mean
Standard Deviation
units on a scale
Title
Denominators
Categories
Title
Measurements
BG00072.66± 16.03
BG00172.42± 17.32
BG00270.95± 16.67
BG00369.54± 18.24
BG00471.08± 17.55
BG00571.38± 17.14
Swollen Joint Count (Out of 66 Joints)
Mean
Standard Deviation
Number of Swollen Joints
Title
Denominators
Categories
Title
Measurements
BG00016.05± 9.79
BG00117.75± 10.86
BG00216.74± 10.11
BG00315.79± 9.40
BG00416.30± 10.05
BG00516.53± 10.06
Tender Joint Count (Out of 68 Joints)
Mean
Standard Deviation
Number of Tender Joints
Title
Denominators
Categories
Title
Measurements
BG00026.91± 14.17
BG00128.33± 15.42
BG00227.19± 14.97
BG00326.76± 14.37
BG00427.25± 16.11
BG00527.30± 15.00
OG002
Etoricoxib 30 mg
Treatment I: Etoricoxib 30 mg orally once daily
OG003
Etoricoxib 60 mg
Treatment I: Etoricoxib 60 mg orally once daily
OG004
Etoricoxib 90 mg
Treatment I: Etoricoxib 90 mg orally once daily
Units
Counts
Participants
OG000161
OG001154
OG002151
OG003140
OG004155
Title
Denominators
Categories
Title
Measurements
OG00028.57
OG00135.06
OG00237.75
OG00338.57
OG00447.10
Group IDs
Group Description
Statistical Method
Statistical Comment
P-Value
P-Value Comment
Parameter Type
Parameter Value
Dispersion Type
Dispersion Value
Confidence Interval Sides
Confidence Interval %
CI Lower Limit
CI Upper Limit
CI Lower Limit Comment
CI Upper Limit Comment
Estimate Comment
Tested Non-Inferiority
Non-Inferiority Type
Non-Inferiority Comment
Other Analysis Description
OG000
OG001
OG002
OG003
OG004
Cochran-Armitage trend test
A step-down procedure and Abelson-Tukey scaling were used for the trend test.
<0.001
Overall alpha=0.05 for multiple comparisons with a step-down procedure (p-values subsequent to the first non-significant p-value were not reported).
95
Superiority or Other (legacy)
OG000
OG001
OG002
OG003
Cochran-Armitage trend test
A step-down procedure and Abelson-Tukey scaling were used for the trend test.
0.057
Overall alpha=0.05 for multiple comparisons with a step-down procedure (p-values subsequent to the first non-significant p-value were not reported).
95
Superiority or Other (legacy)
OG000
OG004
difference in percentage of patients
18.53
95
7.84
28.65
CI based on the Wilson's score method.
Superiority or Other (legacy)
OG000
OG003
difference in percentage of patients
10.00
95
-0.66
20.46
CI based on the Wilson's score method.
Superiority or Other (legacy)
OG000
OG002
difference in percentage of patients
9.18
95
-1.25
19.39
CI based on the Wilson's score method.
Superiority or Other (legacy)
OG000
OG001
difference in percentage of patients
6.49
95
-3.76
16.61
CI based on the Wilson's score method.
Superiority or Other (legacy)
Secondary
Tender Joint Count (Out of 68 Joints) Time-Weighted Average Change From Baseline (Flare/Randomization Visit) in the 12-Week Treatment Period (All Patients-Treated Population)
All-Patients-Treatment Population
Posted
Mean
Standard Deviation
Tender Joint Count
Time-weighted average change from baseline across Weeks 2, 7, and 12
ID
Title
Description
OG000
Placebo
Treatment I: Placebo orally once daily
OG001
Etoricoxib 10 mg
Treatment I: Etoricoxib 10 mg orally once daily
OG002
Etoricoxib 30 mg
Treatment I: Etoricoxib 30 mg orally once daily
OG003
Etoricoxib 60 mg
Treatment I: Etoricoxib 60 mg orally once daily
OG004
Etoricoxib 90 mg
Treatment I: Etoricoxib 90 mg orally once daily
Units
Counts
Participants
OG000157
OG001148
OG002146
OG003
Title
Denominators
Categories
Title
Measurements
OG000-8.13± 9.55
OG001-11.01± 13.07
OG002-10.96± 11.00
OG003
Group IDs
Group Description
Statistical Method
Statistical Comment
P-Value
P-Value Comment
Parameter Type
Parameter Value
Dispersion Type
Dispersion Value
Confidence Interval Sides
Confidence Interval %
CI Lower Limit
CI Upper Limit
CI Lower Limit Comment
CI Upper Limit Comment
Estimate Comment
Tested Non-Inferiority
Non-Inferiority Type
Non-Inferiority Comment
Other Analysis Description
OG000
OG001
OG002
OG003
OG004
ANCOVA
Based on a trend test with a step-down procedure and Abelson-Tukey scaling.
0.002
Overall alpha=0.05 for multiple comparisons with a step-down procedure (p-values subsequent to the first non-significant p-value were not reported).
95
Superiority or Other (legacy)
Secondary
Swollen Joint Count (Out of 66 Joints) Time-Weighted Average Change From Baseline (Flare/Randomization Visit) in the 12-Week Treatment Period (All Patients-Treated Population)
All-Patients-Treatment Population
Posted
Mean
Standard Deviation
Swollen Joint Count
Time-weighted average change from baseline across Weeks 2, 7, and 12
ID
Title
Description
OG000
Placebo
Treatment I: Placebo orally once daily
OG001
Etoricoxib 10 mg
Treatment I: Etoricoxib 10 mg orally once daily
OG002
Etoricoxib 30 mg
Treatment I: Etoricoxib 30 mg orally once daily
OG003
Etoricoxib 60 mg
Treatment I: Etoricoxib 60 mg orally once daily
OG004
Etoricoxib 90 mg
Treatment I: Etoricoxib 90 mg orally once daily
Units
Counts
Participants
OG000157
OG001148
OG002146
OG003
Title
Denominators
Categories
Title
Measurements
OG000-5.39± 7.34
OG001-6.58± 8.11
OG002-6.91± 7.27
OG003
Group IDs
Group Description
Statistical Method
Statistical Comment
P-Value
P-Value Comment
Parameter Type
Parameter Value
Dispersion Type
Dispersion Value
Confidence Interval Sides
Confidence Interval %
CI Lower Limit
CI Upper Limit
CI Lower Limit Comment
CI Upper Limit Comment
Estimate Comment
Tested Non-Inferiority
Non-Inferiority Type
Non-Inferiority Comment
Other Analysis Description
OG000
OG001
OG002
OG003
OG004
ANCOVA
Based on a trend test with a step-down procedure and Abelson-Tukey scaling.
0.001
Overall alpha=0.05 for multiple comparisons with a step-down procedure (p-values subsequent to the first non-significant p-value were not reported).
95
Superiority or Other (legacy)
Secondary
Patient Global Assessment of Disease Activity (0- to 100-mm Visual Analog Scale) Time Weighted Average Change From Baseline (Flare/Randomization Visit) in the 12-Week Treatment I Period (All Patients-Treated Population)
0-mm indicates very well, 100-mm indicates very poor.
All Patients-Treated Population
Posted
Mean
Standard Deviation
Units on a Scale
Time-weighted average change from baseline across Weeks 2, 7, and 12
ID
Title
Description
OG000
Placebo
Treatment I: Placebo orally once daily
OG001
Etoricoxib 10 mg
Treatment I: Etoricoxib 10 mg orally once daily
OG002
Etoricoxib 30 mg
Treatment I: Etoricoxib 30 mg orally once daily
OG003
Etoricoxib 60 mg
Treatment I: Etoricoxib 60 mg orally once daily
OG004
Etoricoxib 90 mg
Treatment I: Etoricoxib 90 mg orally once daily
Units
Counts
Participants
OG000155
OG001144
OG002141
OG003
Title
Denominators
Categories
Title
Measurements
OG000-12.32± 25.66
OG001-19.90± 23.61
OG002-21.12± 24.47
OG003
Group IDs
Group Description
Statistical Method
Statistical Comment
P-Value
P-Value Comment
Parameter Type
Parameter Value
Dispersion Type
Dispersion Value
Confidence Interval Sides
Confidence Interval %
CI Lower Limit
CI Upper Limit
CI Lower Limit Comment
CI Upper Limit Comment
Estimate Comment
Tested Non-Inferiority
Non-Inferiority Type
Non-Inferiority Comment
Other Analysis Description
OG000
OG001
OG002
OG003
OG004
ANCOVA
Based on a trend test with a step-down procedure and Abelson-Tukey scaling.
<0.001
Overall alpha=0.05 for multiple comparisons with a step-down procedure (p-values subsequent to the first non-significant p-value were not reported).
95
Superiority or Other (legacy)
Secondary
Investigator Global Assessment of Disease Activity (0- to 4-Likert Scale) Time Weighted Average Change From Baseline (Flare/Randomization Visit) in the 12-Week Treatment I Period (All Patients-Treated Population)
0 indicates very well, 4 indicates very poor.
All-Patients-Treatment Population
Posted
Mean
Standard Deviation
Units on a Scale
Time-weighted average change from baseline across Weeks 2, 7, and 12
ID
Title
Description
OG000
Placebo
Treatment I: Placebo orally once daily
OG001
Etoricoxib 10 mg
Treatment I: Etoricoxib 10 mg orally once daily
OG002
Etoricoxib 30 mg
Treatment I: Etoricoxib 30 mg orally once daily
OG003
Etoricoxib 60 mg
Treatment I: Etoricoxib 60 mg orally once daily
OG004
Etoricoxib 90 mg
Treatment I: Etoricoxib 90 mg orally once daily
Units
Counts
Participants
OG000157
OG001148
OG002146
OG003
Title
Denominators
Categories
Title
Measurements
OG000-0.68± 1.06
OG001-0.93± 0.94
OG002-1.09± 1.01
OG003
Group IDs
Group Description
Statistical Method
Statistical Comment
P-Value
P-Value Comment
Parameter Type
Parameter Value
Dispersion Type
Dispersion Value
Confidence Interval Sides
Confidence Interval %
CI Lower Limit
CI Upper Limit
CI Lower Limit Comment
CI Upper Limit Comment
Estimate Comment
Tested Non-Inferiority
Non-Inferiority Type
Non-Inferiority Comment
Other Analysis Description
OG000
OG001
OG002
OG003
OG004
ANCOVA
Based on a trend test with a step-down procedure and Abelson-Tukey scaling.
<0.001
Overall alpha=0.05 for multiple comparisons with a step-down procedure (p-values subsequent to the first non-significant p-value were not reported).
95
Superiority or Other (legacy)
Secondary
Patient Global Assessment of Pain (0- to 100-mm Visual Analog Scale) Time Weighted Average Change From Baseline (Flare/Randomization Visit) in the 12-Week Treatment I Period (All Patients-Treated Population)
0-mm indicates very well, 100-mm indicates very poor.
All-Patients-Treated Population
Posted
Mean
Standard Deviation
Units on a Scale
Time-weighted average change from baseline across Weeks 2, 7, and 12
ID
Title
Description
OG000
Placebo
Treatment I: Placebo orally once daily
OG001
Etoricoxib 10 mg
Treatment I: Etoricoxib 10 mg orally once daily
OG002
Etoricoxib 30 mg
Treatment I: Etoricoxib 30 mg orally once daily
OG003
Etoricoxib 60 mg
Treatment I: Etoricoxib 60 mg orally once daily
OG004
Etoricoxib 90 mg
Treatment I: Etoricoxib 90 mg orally once daily
Units
Counts
Participants
OG000157
OG001148
OG002146
OG003
Title
Denominators
Categories
Title
Measurements
OG000-17.44± 23.42
OG001-21.95± 22.87
OG002-22.75± 23.86
OG003
Group IDs
Group Description
Statistical Method
Statistical Comment
P-Value
P-Value Comment
Parameter Type
Parameter Value
Dispersion Type
Dispersion Value
Confidence Interval Sides
Confidence Interval %
CI Lower Limit
CI Upper Limit
CI Lower Limit Comment
CI Upper Limit Comment
Estimate Comment
Tested Non-Inferiority
Non-Inferiority Type
Non-Inferiority Comment
Other Analysis Description
OG000
OG001
OG002
OG003
OG004
ANCOVA
Based on a trend test with a step-down procedure and Abelson-Tukey scaling.
<0.001
Overall alpha=0.05 for multiple comparisons with a step-down procedure (p-values subsequent to the first non-significant p-value were not reported).
95
Superiority or Other (legacy)
0
28
EG001
Etoricoxib 10 mg Treatment I Period
Treatment I: Etoricoxib 10 mg orally once daily
1
19
EG002
Etoricoxib 30 mg Treatment I Period
Treatment I: Etoricoxib 30 mg orally once daily
4
29
EG003
Etoricoxib 60 mg Treatment I Period
Treatment I: Etoricoxib 60 mg orally once daily
1
37
EG004
Etoricoxib 90 mg Treatment I Period
Treatment I: Etoricoxib 90 mg orally once daily
5
39
EG005
Etoricoxib 90 mg Treatment II Period
Treatment II: Etoricoxib 90 mg orally once daily
3
25
EG006
Diclofenac 150 mg Treatment II Period
Treatment II: Diclofenac 75 mg orally twice daily
3
30
EG0000 affected161 at risk
EG0010 affected154 at risk
EG0021 affected151 at risk
EG0030 affected140 at risk
EG0040 affected155 at risk
EG0050 affected180 at risk
EG0060 affected149 at risk
Myocardial Infarction
Cardiac disorders
MedDRA 10.1
Non-systematic Assessment
EG0000 affected161 at risk
EG0010 affected154 at risk
EG0021 affected151 at risk
EG0030 affected140 at risk
EG0040 affected155 at risk
EG0050 affected180 at risk
EG0060 affected149 at risk
Gastritis
Gastrointestinal disorders
MedDRA 10.1
Non-systematic Assessment
EG0000 affected161 at risk
EG0010 affected154 at risk
EG0021 affected151 at risk
EG0030 affected140 at risk
EG0040 affected155 at risk
EG0050 affected180 at risk
EG0060 affected149 at risk
Ileus Paralytic
Gastrointestinal disorders
MedDRA 10.1
Non-systematic Assessment
EG0000 affected161 at risk
EG0010 affected154 at risk
EG0021 affected151 at risk
EG0030 affected140 at risk
EG0040 affected155 at risk
EG0050 affected180 at risk
EG0060 affected149 at risk
Small Intestinal Obstruction
Gastrointestinal disorders
MedDRA 10.1
Non-systematic Assessment
EG0000 affected161 at risk
EG0010 affected154 at risk
EG0020 affected151 at risk
EG0030 affected140 at risk
EG0041 affected155 at risk
EG0050 affected180 at risk
EG0060 affected149 at risk
Cellulitis
Infections and infestations
MedDRA 10.1
Non-systematic Assessment
EG0000 affected161 at risk
EG0010 affected154 at risk
EG0020 affected151 at risk
EG0030 affected140 at risk
EG0041 affected155 at risk
EG0050 affected180 at risk
EG0060 affected149 at risk
Erysipelas
Infections and infestations
MedDRA 10.1
Non-systematic Assessment
EG0000 affected161 at risk
EG0010 affected154 at risk
EG0021 affected151 at risk
EG0030 affected140 at risk
EG0040 affected155 at risk
EG0050 affected180 at risk
EG0060 affected149 at risk
Accidental Overdose
Injury, poisoning and procedural complications
MedDRA 10.1
Non-systematic Assessment
EG0000 affected161 at risk
EG0010 affected154 at risk
EG0020 affected151 at risk
EG0030 affected140 at risk
EG0040 affected155 at risk
EG0050 affected180 at risk
EG0061 affected149 at risk
Dislocation Of Joint Prosthesis
Injury, poisoning and procedural complications
MedDRA 10.1
Non-systematic Assessment
EG0000 affected161 at risk
EG0010 affected154 at risk
EG0020 affected151 at risk
EG0030 affected140 at risk
EG0041 affected155 at risk
EG0050 affected180 at risk
EG0060 affected149 at risk
Femoral Neck Fracture
Injury, poisoning and procedural complications
MedDRA 10.1
Non-systematic Assessment
EG0000 affected161 at risk
EG0010 affected154 at risk
EG0020 affected151 at risk
EG0030 affected140 at risk
EG0040 affected155 at risk
EG0051 affected180 at risk
EG0060 affected149 at risk
Heat Exhaustion
Injury, poisoning and procedural complications
MedDRA 10.1
Non-systematic Assessment
EG0000 affected161 at risk
EG0010 affected154 at risk
EG0020 affected151 at risk
EG0030 affected140 at risk
EG0041 affected155 at risk
EG0050 affected180 at risk
EG0060 affected149 at risk
Blood Creatinine Increased
Investigations
MedDRA 10.1
Non-systematic Assessment
EG0000 affected161 at risk
EG0010 affected154 at risk
EG0020 affected151 at risk
EG0031 affected140 at risk
EG0040 affected155 at risk
EG0050 affected180 at risk
EG0060 affected149 at risk
Intervertebral Disc Disorder
Musculoskeletal and connective tissue disorders
MedDRA 10.1
Non-systematic Assessment
EG0000 affected161 at risk
EG0010 affected154 at risk
EG0021 affected151 at risk
EG0030 affected140 at risk
EG0040 affected155 at risk
EG0050 affected180 at risk
EG0060 affected149 at risk
Malignant Melanoma In Situ
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MedDRA 10.1
Non-systematic Assessment
EG0000 affected161 at risk
EG0010 affected154 at risk
EG0020 affected151 at risk
EG0030 affected140 at risk
EG0040 affected155 at risk
EG0050 affected180 at risk
EG0061 affected149 at risk
Depression
Psychiatric disorders
MedDRA 10.1
Non-systematic Assessment
EG0000 affected161 at risk
EG0010 affected154 at risk
EG0020 affected151 at risk
EG0030 affected140 at risk
EG0041 affected155 at risk
EG0050 affected180 at risk
EG0060 affected149 at risk
Obsessive-Compulsive Disorder
Psychiatric disorders
MedDRA 10.1
Non-systematic Assessment
EG0000 affected161 at risk
EG0010 affected154 at risk
EG0020 affected151 at risk
EG0030 affected140 at risk
EG0040 affected155 at risk
EG0050 affected180 at risk
EG0061 affected149 at risk
Ovarian Cyst
Reproductive system and breast disorders
MedDRA 10.1
Non-systematic Assessment
EG0000 affected161 at risk
EG0010 affected154 at risk
EG0020 affected151 at risk
EG0030 affected140 at risk
EG0040 affected155 at risk
EG0051 affected180 at risk
EG0060 affected149 at risk
Haemothorax
Respiratory, thoracic and mediastinal disorders
MedDRA 10.1
Non-systematic Assessment
EG0000 affected161 at risk
EG0010 affected154 at risk
EG0021 affected151 at risk
EG0030 affected140 at risk
EG0040 affected155 at risk
EG0050 affected180 at risk
EG0060 affected149 at risk
Dermatitis
Skin and subcutaneous tissue disorders
MedDRA 10.1
Non-systematic Assessment
EG0000 affected161 at risk
EG0010 affected154 at risk
EG0020 affected151 at risk
EG0030 affected140 at risk
EG0040 affected155 at risk
EG0051 affected180 at risk
EG0060 affected149 at risk
Hypertension
Vascular disorders
MedDRA 10.1
Non-systematic Assessment
EG0000 affected161 at risk
EG0011 affected154 at risk
EG0020 affected151 at risk
EG0030 affected140 at risk
EG0040 affected155 at risk
EG0050 affected180 at risk
EG0060 affected149 at risk
EG0000 affected161 at risk
EG0010 affected154 at risk
EG0020 affected151 at risk
EG0030 affected140 at risk
EG0041 affected155 at risk
EG0050 affected180 at risk
EG0063 affected149 at risk
Abdominal Pain Upper
Gastrointestinal disorders
MedDRA 10.1
Non-systematic Assessment
EG0002 affected161 at risk
EG0011 affected154 at risk
EG0021 affected151 at risk
EG0033 affected140 at risk
EG0042 affected155 at risk
EG0050 affected180 at risk
EG0062 affected149 at risk
Constipation
Gastrointestinal disorders
MedDRA 10.1
Non-systematic Assessment
EG0000 affected161 at risk
EG0011 affected154 at risk
EG0025 affected151 at risk
EG0033 affected140 at risk
EG0042 affected155 at risk
EG0051 affected180 at risk
EG0061 affected149 at risk
Diarrhoea
Gastrointestinal disorders
MedDRA 10.1
Non-systematic Assessment
EG0003 affected161 at risk
EG0014 affected154 at risk
EG0022 affected151 at risk
EG0038 affected140 at risk
EG0047 affected155 at risk
EG0054 affected180 at risk
EG0066 affected149 at risk
Dyspepsia
Gastrointestinal disorders
MedDRA 10.1
Non-systematic Assessment
EG0005 affected161 at risk
EG0012 affected154 at risk
EG0021 affected151 at risk
EG0033 affected140 at risk
EG0046 affected155 at risk
EG0052 affected180 at risk
EG0064 affected149 at risk
Nausea
Gastrointestinal disorders
MedDRA 10.1
Non-systematic Assessment
EG0002 affected161 at risk
EG0012 affected154 at risk
EG0022 affected151 at risk
EG0033 affected140 at risk
EG0043 affected155 at risk
EG0050 affected180 at risk
EG0062 affected149 at risk
Oedema Peripheral
General disorders
MedDRA 10.1
Non-systematic Assessment
EG0001 affected161 at risk
EG0012 affected154 at risk
EG0022 affected151 at risk
EG0035 affected140 at risk
EG0041 affected155 at risk
EG0056 affected180 at risk
EG0064 affected149 at risk
Nasopharyngitis
Infections and infestations
MedDRA 10.1
Non-systematic Assessment
EG0001 affected161 at risk
EG0014 affected154 at risk
EG0020 affected151 at risk
EG0031 affected140 at risk
EG0044 affected155 at risk
EG0052 affected180 at risk
EG0061 affected149 at risk
Sinusitis
Infections and infestations
MedDRA 10.1
Non-systematic Assessment
EG0003 affected161 at risk
EG0011 affected154 at risk
EG0020 affected151 at risk
EG0031 affected140 at risk
EG0044 affected155 at risk
EG0052 affected180 at risk
EG0061 affected149 at risk
Upper Respiratory Tract Infection
Infections and infestations
MedDRA 10.1
Non-systematic Assessment
EG0004 affected161 at risk
EG0010 affected154 at risk
EG0024 affected151 at risk
EG0031 affected140 at risk
EG0042 affected155 at risk
EG0054 affected180 at risk
EG0067 affected149 at risk
Urinary Tract Infection
Infections and infestations
MedDRA 10.1
Non-systematic Assessment
EG0001 affected161 at risk
EG0011 affected154 at risk
EG0023 affected151 at risk
EG0030 affected140 at risk
EG0040 affected155 at risk
EG0052 affected180 at risk
EG0061 affected149 at risk
Rheumatoid Arthritis
Musculoskeletal and connective tissue disorders
MedDRA 10.1
Non-systematic Assessment
EG0003 affected161 at risk
EG0011 affected154 at risk
EG0023 affected151 at risk
EG0034 affected140 at risk
EG0042 affected155 at risk
EG0051 affected180 at risk
EG0063 affected149 at risk
Dizziness
Nervous system disorders
MedDRA 10.1
Non-systematic Assessment
EG0001 affected161 at risk
EG0011 affected154 at risk
EG0022 affected151 at risk
EG0034 affected140 at risk
EG0046 affected155 at risk
EG0050 affected180 at risk
EG0061 affected149 at risk
Headache
Nervous system disorders
MedDRA 10.1
Non-systematic Assessment
EG0006 affected161 at risk
EG0014 affected154 at risk
EG0025 affected151 at risk
EG0038 affected140 at risk
EG0045 affected155 at risk
EG0052 affected180 at risk
EG0060 affected149 at risk
Cough
Respiratory, thoracic and mediastinal disorders
MedDRA 10.1
Non-systematic Assessment
EG0001 affected161 at risk
EG0011 affected154 at risk
EG0020 affected151 at risk
EG0033 affected140 at risk
EG0042 affected155 at risk
EG0050 affected180 at risk
EG0061 affected149 at risk
Hypertension
Vascular disorders
MedDRA 10.1
Systematic Assessment
EG0000 affected161 at risk
EG0012 affected154 at risk
EG0023 affected151 at risk
EG0036 affected140 at risk
EG0045 affected155 at risk
EG0056 affected180 at risk
EG0061 affected149 at risk
OTHER
Results Disclosure Restriction on PI(s)?
Yes
Other Details
Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.
D003240
Connective Tissue Diseases
D017437
Skin and Connective Tissue Diseases
D001327
Autoimmune Diseases
D007154
Immune System Diseases
D006573
Heterocyclic Compounds, 1-Ring
D006571
Heterocyclic Compounds
0 subjects
FG0051 subjects
20 subjects
FG00519 subjects
1 subjects
FG0051 subjects
3 subjects
FG0052 subjects
0 subjects
FG0051 subjects
33
BG005148
73
BG00498
BG005439
26
BG00419
BG005101
99
BG004106
BG005529
26
BG00424
BG005132
21
BG00419
BG005107
47
BG00462
BG005289
7
BG0046
BG00529
96
BG004112
BG005549
34
BG00436
BG005175
2
BG0040
BG0053
0
BG0040
BG0051
20
BG00434
BG005161
0
BG0040
BG0051
39
BG00440
BG005220
78
BG00493
BG005412
138
OG004148
-9.56
± 11.85
OG004-12.06± 11.22
OG000
OG001
OG002
OG003
ANCOVA
Based on a trend test with a step-down procedure and Abelson-Tukey scaling.
0.221
Overall alpha=0.05 for multiple comparisons with a step-down procedure (p-values subsequent to the first non-significant p-value were not reported).
95
Superiority or Other (legacy)
OG000
OG004
Mean Difference (Final Values)
-4.06
95
-6.44
-1.68
Superiority or Other (legacy)
OG000
OG003
Mean Difference (Final Values)
-1.49
95
-3.91
0.93
Superiority or Other (legacy)
OG000
OG002
Mean Difference (Final Values)
-2.74
95
-5.13
-0.35
Superiority or Other (legacy)
OG000
OG001
Mean Difference (Final Values)
-2.50
95
-4.88
-0.12
Superiority or Other (legacy)
138
OG004148
-6.25
± 7.48
OG004-7.77± 7.17
OG000
OG001
OG002
OG003
ANCOVA
Based on a trend test with a step-down procedure and Abelson-Tukey scaling.
0.125
Overall alpha=0.05 for multiple comparisons with a step-down procedure (p-values subsequent to the first non-significant p-value were not reported).
95
Superiority or Other (legacy)
OG000
OG004
Mean Difference (Final Values)
-2.24
95
-3.64
-0.84
Superiority or Other (legacy)
OG000
OG003
Mean Difference (Final Values)
-1.02
95
-2.44
0.41
Superiority or Other (legacy)
OG000
OG002
Mean Difference (Final Values)
-1.22
95
-2.63
0.18
Superiority or Other (legacy)
OG000
OG001
Mean Difference (Final Values)
-0.49
95
-1.89
0.91
Superiority or Other (legacy)
134
OG004144
-21.49
± 26.71
OG004-25.75± 25.71
OG000
OG001
OG002
OG003
ANCOVA
Based on a trend test with a step-down procedure and Abelson-Tukey scaling.
<0.001
Overall alpha=0.05 for multiple comparisons with a step-down procedure (p-values subsequent to the first non-significant p-value were not reported).
95
Superiority or Other (legacy)
OG000
OG001
OG002
ANCOVA
Based on a trend test with a step-down procedure and Abelson-Tukey scaling.
<0.001
Overall alpha=0.05 for multiple comparisons with a step-down procedure (p-values subsequent to the first non-significant p-value were not reported).
95
Superiority or Other (legacy)
OG000
OG001
ANCOVA
Based on a trend test with a step-down procedure and Abelson-Tukey scaling.
0.023
Overall alpha=0.05 for multiple comparisons with a step-down procedure (p-values subsequent to the first non-significant p-value were not reported).
95
Superiority or Other (legacy)
OG000
OG004
Mean Difference (Final Values)
-14.16
95
-19.38
-8.95
Superiority or Other (legacy)
OG000
OG003
Mean Difference (Final Values)
-9.21
95
-14.52
-3.90
Superiority or Other (legacy)
OG000
OG002
Mean Difference (Final Values)
-8.87
95
-14.11
-3.63
Superiority or Other (legacy)
OG000
OG001
Mean Difference (Final Values)
-6.05
95
-11.27
-0.83
Superiority or Other (legacy)
138
OG004148
-1.01
± 0.94
OG004-1.24± 0.94
OG000
OG001
OG002
OG003
ANCOVA
Based on a trend test with a step-down procedure and Abelson-Tukey scaling.
<0.001
Overall alpha=0.05 for multiple comparisons with a step-down procedure (p-values subsequent to the first non-significant p-value were not reported).
95
Superiority or Other (legacy)
OG000
OG001
OG002
ANCOVA
Based on a trend test with a step-down procedure and Abelson-Tukey scaling.
<0.001
Overall alpha=0.05 for multiple comparisons with a step-down procedure (p-values subsequent to the first non-significant p-value were not reported).
95
Superiority or Other (legacy)
OG000
OG001
ANCOVA
Based on a trend test with a step-down procedure and Abelson-Tukey scaling.
0.018
Overall alpha=0.05 for multiple comparisons with a step-down procedure (p-values subsequent to the first non-significant p-value were not reported).
95
Superiority or Other (legacy)
OG000
OG004
Mean Difference (Final Values)
-0.56
95
-0.77
-0.35
Superiority or Other (legacy)
OG000
OG003
Mean Difference (Final Values)
-0.34
95
-0.55
-0.13
Superiority or Other (legacy)
OG000
OG002
Mean Difference (Final Values)
-0.40
95
-0.61
-0.19
Superiority or Other (legacy)
OG000
OG001
Mean Difference (Final Values)
-0.25
95
-0.46
-0.04
Superiority or Other (legacy)
137
OG004148
-22.25
± 26.58
OG004-31.07± 24.18
OG000
OG001
OG002
OG003
ANCOVA
Based on a trend test with a step-down procedure and Abelson-Tukey scaling.
0.018
Overall alpha=0.05 for multiple comparisons with a step-down procedure (p-values subsequent to the first non-significant p-value were not reported).
95
Superiority or Other (legacy)
OG000
OG001
OG002
ANCOVA
Based on a trend test with a step-down procedure and Abelson-Tukey scaling.
0.017
Overall alpha=0.05 for multiple comparisons with a step-down procedure (p-values subsequent to the first non-significant p-value were not reported).
95
Superiority or Other (legacy)
OG000
OG001
ANCOVA
Based on a trend test with a step-down procedure and Abelson-Tukey scaling.
0.080
Overall alpha=0.05 for multiple comparisons with a step-down procedure (p-values subsequent to the first non-significant p-value were not reported).